PF 4764793Alternative Names: PF-00241939; PF-04764793; PF-241939; PF-4764793
Latest Information Update: 15 Nov 2011
At a glance
- Originator Pfizer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 10 Nov 2011 Discontinued - Phase-I for Asthma in Singapore (Inhalation)
- 11 May 2011 Pfizer completes a phase I trial in Healthy volunteers in Singapore (NCT01272375)